China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999

Watchlist Manager
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Logo
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
Watchlist
Price: 46.55 CNY 0.67% Market Closed
Market Cap: 59.8B CNY
Have any thoughts about
China Resources Sanjiu Medical & Pharmaceutical Co Ltd?
Write Note

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
Cash from Investing Activities
-ÂĄ3.1B
CAGR 3-Years
-192%
CAGR 5-Years
-35%
CAGR 10-Years
-19%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Investing Activities
ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Investing Activities
ÂĄ7B
CAGR 3-Years
N/A
CAGR 5-Years
61%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Investing Activities
-ÂĄ1.9B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
-25%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Investing Activities
-ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
3%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Investing Activities
-ÂĄ81.9m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Glance View

Market Cap
59.8B CNY
Industry
Pharmaceuticals

In the intricate landscape of China's healthcare sector, China Resources Sanjiu Medical & Pharmaceutical Co Ltd stands as a significant player, weaving its extensive roots in both traditional and modern medicine. Emerging from the fusion of innovation and heritage, the company operates under the wing of China Resources, a state-owned conglomerate. This affiliation affords it a robust platform to traverse the dual path of pharmaceutical manufacturing and healthcare services. The company primarily engages in the development, production, and sale of a diverse range of pharmaceutical products, from essential medicines to over-the-counter dietary supplements. These offerings include both Western-style pharmaceuticals and traditional Chinese medicines, such as its widely recognized "999" branded cold medicines, allowing the company to leverage its expertise in a market with growing demand for holistic health solutions. China Resources Sanjiu generates its revenue through multiple channels, capitalizing on both domestic and international market opportunities. By integrating research and development with an efficient distribution network, the company ensures that its products reach a broad consumer base. In recent years, the company has focused on enhancing its research capabilities, investing heavily in developing innovative drugs that address prevalent health challenges. Sales of their proprietary and branded products are supported by strategic marketing initiatives, which highlight Sanjiu's commitment to quality and efficacy. Furthermore, the company's synergy with its parent organization facilitates expansions and strategic partnerships, reinforcing its competitive advantage in an industry marked by rapid evolution and stringent regulatory landscapes. With a foothold in both retail and institutional markets, China Resources Sanjiu Medical & Pharmaceutical Co Ltd continues to play a pivotal role in enhancing access to healthcare across China and beyond.

Intrinsic Value
58.69 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
-3.1B CNY

Based on the financial report for Sep 30, 2024, China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Cash from Investing Activities amounts to -3.1B CNY.

What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-19%

Over the last year, the Cash from Investing Activities growth was -220%. The average annual Cash from Investing Activities growth rates for China Resources Sanjiu Medical & Pharmaceutical Co Ltd have been -192% over the past three years , -35% over the past five years , and -19% over the past ten years .

Back to Top